Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US.

MLA

Pelton, Stephen I., et al. “Modelling the Population-Level Benefits and Cost-Effectiveness of Cell-Based Quadrivalent Influenza Vaccine for Children and Adolescents Aged 6 Months to 17 Years in the US.” Expert Review of Vaccines, vol. 23, no. 1, Jan. 2024, pp. 82–87. EBSCOhost, https://doi.org/10.1080/14760584.2023.2295014.

APA

Pelton, S. I., Mould-Quevedo, J. F., & Nguyen, V. H. (2024). Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US. Expert Review of Vaccines, 23(1), 82–87. https://doi.org/10.1080/14760584.2023.2295014

Chicago

Pelton, Stephen I., Joaquin F. Mould-Quevedo, and Van Hung Nguyen. 2024. “Modelling the Population-Level Benefits and Cost-Effectiveness of Cell-Based Quadrivalent Influenza Vaccine for Children and Adolescents Aged 6 Months to 17 Years in the US.” Expert Review of Vaccines 23 (1): 82–87. doi:10.1080/14760584.2023.2295014.